Results 261 to 270 of about 224,997 (329)

Differentially expressed genes and therapeutic targets for nonalcoholic fatty liver disease from transcriptomic techniques. [PDF]

Medicine (Baltimore)
Li J, Li Y, Zhang Y, Zhang S.
europepmc   +1 more source

Wernicke’s Encephalopathy Secondary to Hyperemesis Gravidarum in Pregnancy: A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Wernicke's Encephalopathy, although classically associated with chronic alcoholism, can also occur during pregnancy as a complication of hyperemesis gravidarum and is often underdiagnosed. We report a case of a 34‐year‐old pregnant woman at 16 weeks of gestation who presented with prolonged vomiting, altered mental status, nystagmus, and gait ...
Abhishek Mahato, Sameer Parajuli, Bandana Ghimire, Bishal Basnet, Bishal Sigdel, Bishal Kumar Yadav, Sagar Kumar Jha   +6 more
wiley   +1 more source

Prevalence of Nonalcoholic Fatty Liver Disease in Obese Patients and its Association with Insulin Resistance Markers.

J Pharm Bioallied Sci
Nayak J, Luke NE, Deshpande AV, Gupta S, Saiyad H, Farooqui S.   +5 more
europepmc   +1 more source

miRNAs, lncRNAs, circRNAs and piRNAs in Nonalcoholic Fatty Liver Disease: Past, Present and Future. [PDF]

Int J Mol Sci
Lucaciu RL, Orasan OH, Hangan AC, Iancu M, Cozma A, Coste SC, Gog-Bogdan S, Sevastre B, Procopciuc LM.   +8 more
europepmc   +1 more source

Fibroblast growth factor 10 attenuates advanced liver fibrosis through hepatocyte fibroblast growth factor receptor 2 signalling

Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
FGF10‐FGFR2 signaling is progressively impaired during liver fibrosis. FGF10 restoration protects hepatocytes from inflammatory and apoptotic injury. Hepatocyte FGFR2 mediates FGF10‐driven suppression of fibrogenic remodeling through the GSK3β/NF‐κB axis.
Xuanxin Yang, Qingqing Dong, Jiaying Ma, Yawei Yan, Shuangyan Peng, Qiqi Wu, Huan Wang, Tingting Zhang, Panyu Zhang, Zelong Jiang, Chao Lu, Le Li, Xinyi You, Yuandong Xu, Joshua Banda, Zhixiang Mu, Minghua Zheng, Xiaokun Li, Qi Hui, Bingjie Yu, Xiaojie Wang   +20 more
wiley   +1 more source

Causal validation of immune antibody responses and nonalcoholic fatty liver disease: Evidence from Mendelian randomization and meta-analysis. [PDF]

Medicine (Baltimore)
Zhao Z, Guo Y, Hong S, Miao L.
europepmc   +1 more source

Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction‐Associated Steatohepatitis: A Network Meta‐Analysis of Randomized Controlled Trials

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
This meta‐analysis compared Resmetirom and Efruxifermin in patients with MASH, focusing on improvements in key biochemical and non‐invasive markers. Efruxifermin is associated with favourable outcomes with a slightly greater effect on MRI‐PDFF and AST, along with more comparable safety outcomes.
Doha Jaber, Inas Jaber, Ayah Abu Lehia, Thekrayat Asad, Hazem Ayesh   +4 more
wiley   +1 more source

Perspectives of Indian Gastroenterologists and Hepatologists on Nonalcoholic Fatty Liver Disease Diagnosis and Management: Insights From the Nationwide Web-Based Cross-Sectional DRIVE Survey. [PDF]

Interact J Med Res
Arora A, Garje Y, Shaikh S, Dharmadhikari S, Khandhedia C, Markandeywar N, Mane A, Mehta SC, Kumar A.   +8 more
europepmc   +1 more source

Targeting of Gut Microbiota by Bioactive Peptides for the Improvement of Metabolic Diseases: A Review

Food Frontiers, Volume 7, Issue 3, May 2026.
Bioactive peptides (BPs) derived from dietary proteins modulate the gut microbiotametabolism axis by reshaping microbial composition and regulating key metabolites, including short‐chain fatty acids. BPs also enhance intestinal barrier integrity and immune homeostasis, thereby reducing inflammation.
Jiao Li, Yongchao Chen, Zhihua Li, Gang Liu, Hongmei Jiang, Jun Fang, Sujuan Ding   +6 more
wiley   +1 more source

Application of probiotic therapy in nonalcoholic fatty liver disease: mediating mechanism and future perspective. [PDF]

Front Cell Infect Microbiol
Luo XY, Huang WB, Lu CH, Gu W, Feng ZX, Shen S, Chen MZ, Zheng SS, Yang Z.   +8 more
europepmc   +1 more source